WASHINGTON — The rhetoric has come from lawmakers and doctors, entertainers and academics, and even from President Trump: The pharmaceutical industry, all have said, is in large part to blame for the ongoing opioid crisis.
But even amid an epidemic that took nearly 50,000 American lives in 2016, lawmakers have remained reluctant to bring pharmaceutical executives to Capitol Hill and question them face to face.
That will change Tuesday, when the House Energy and Commerce Committee will question a quintet of executives — not from pharmaceutical manufacturers, but instead from drug distributors it has spent the last year investigating.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
